Hearse D J, Yamamoto F, Shattock M J
Circulation. 1984 Sep;70(3 Pt 2):I54-64.
Using an isolated rat heart preparation under both aerobic and ischemic conditions we have characterized the temperature dependency of the slow calcium channel-blocking drug verapamil. In the first series of studies, isolated working rat hearts were subjected to global ischemia at 37 degrees, 34 degrees, 31 degrees, 29 degrees, 27 degrees, 25 degrees, and 20 degrees C. The duration of ischemic arrest was adjusted so that in the control group the postischemic recovery of function (aortic flow) was approximately 50% of its preischemic value. Ischemic times were therefore 35, 50, 55, 60, 80, 100, and 130 min, respectively. In all cases hearts were subjected to 3 min preischemic infusion with St. Thomas' cardioplegic solution with or without added verapamil (1.1 mumol/liter). At 37 degrees C verapamil increased recovery by 36.6 +/- 4.8%; this increased to 57.4 +/- 6.0% at 34 degrees C. Below 34 degrees C, however, additional protection was progressively lost, so that at 27 degrees C or below verapamil contributed no significant additional protection. In separate aerobic perfusion studies with paced Langendorff-prepared hearts with intraventricular balloons, verapamil (0.2 mumol/liter) was shown to depress pressure development by up to 76% at 37 degrees C; this increased to 92% at 34 degrees C, but thereafter the drug's negative inotropic effects declined, so that at 24 degrees C and below there was no significant difference in developed pressure between the control and drug-treated groups. On the basis of these and other studies, the argument is advanced that by some mechanism common to both hypothermia and verapamil, the anti-ischemic and negative inotropic effects of verapamil are rendered redundant under conditions of hypothermia.
在有氧和缺血条件下,我们使用离体大鼠心脏标本,对钙通道阻滞剂维拉帕米的温度依赖性进行了表征。在第一组研究中,将离体工作大鼠心脏分别置于37℃、34℃、31℃、29℃、27℃、25℃和20℃进行全心缺血。调整缺血停搏时间,使对照组缺血后功能(主动脉血流)恢复至缺血前值的约50%。因此,缺血时间分别为35、50、55、60、80、100和130分钟。在所有情况下,心脏在缺血前用或不用维拉帕米(1.1μmol/L)的圣托马斯心脏停搏液灌注3分钟。在37℃时,维拉帕米使恢复率提高了36.6±4.8%;在34℃时,这一比例增至57.4±6.0%。然而,在34℃以下,额外的保护作用逐渐丧失,因此在27℃及以下,维拉帕米没有显著的额外保护作用。在另一项对带心室内球囊的Langendorff制备心脏进行的有氧灌注研究中,维拉帕米(0.2μmol/L)在37℃时可使压力升高降低多达76%;在34℃时,这一比例增至92%,但此后该药物的负性肌力作用下降,因此在24℃及以下,对照组和药物治疗组之间的压力升高没有显著差异。基于这些研究和其他研究,有人提出,由于低温和维拉帕米存在某种共同机制,在低温条件下,维拉帕米的抗缺血和负性肌力作用变得多余。